Prenen H - Search Results

1

Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors.

Hofheinz RD, Segaert S, Safont MJ, Demonty G, Prenen H. Hofheinz RD, et al. Among authors: prenen h. Crit Rev Oncol Hematol. 2017 Jun;114:102-113. doi: 10.1016/j.critrevonc.2017.03.032. Epub 2017 Apr 11. Crit Rev Oncol Hematol. 2017. PMID: 28477738 Free article. Review.

2

Cellular senescence in cancer: clinical detection and prognostic implications.

Domen A, Deben C, Verswyvel J, Flieswasser T, Prenen H, Peeters M, Lardon F, Wouters A. Domen A, et al. Among authors: prenen h. J Exp Clin Cancer Res. 2022 Dec 27;41(1):360. doi: 10.1186/s13046-022-02555-3. J Exp Clin Cancer Res. 2022. PMID: 36575462 Free PMC article. Review.

3

New Developments in Treating RAS-Mutated Metastatic Colorectal Cancer.

Janssens K, Lambrechts C, Geerinckx B, Op de Beeck K, Van Camp G, Oliveres H, Prenen H, Vandamme T, Peeters M. Janssens K, et al. Among authors: prenen h. Curr Treat Options Oncol. 2023 Aug;24(8):965-987. doi: 10.1007/s11864-023-01095-y. Epub 2023 May 22. Curr Treat Options Oncol. 2023. PMID: 37212934 Review.

4

Salivary gland carcinomas: molecular abnormalities as potential therapeutic targets.

Prenen H, Kimpe M, Nuyts S. Prenen H, et al. Curr Opin Oncol. 2008 May;20(3):270-4. doi: 10.1097/CCO.0b013e3282f4cf5f. Curr Opin Oncol. 2008. PMID: 18391625 Review.

5

New therapeutic developments in renal cell cancer.

Prenen H, Gil T, Awada A. Prenen H, et al. Crit Rev Oncol Hematol. 2009 Jan;69(1):56-63. doi: 10.1016/j.critrevonc.2008.07.007. Epub 2008 Aug 26. Crit Rev Oncol Hematol. 2009. PMID: 18752971 Review.

6

PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.

Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, Lambrechts D, Van Cutsem E, Tejpar S. Prenen H, et al. Clin Cancer Res. 2009 May 1;15(9):3184-8. doi: 10.1158/1078-0432.CCR-08-2961. Epub 2009 Apr 14. Clin Cancer Res. 2009. PMID: 19366826 Clinical Trial.

7

Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: the role of anti-VEGF and anti-EGFR antibodies.

Geva R, Prenen H, Topal B, Aerts R, Vannoote J, Van Cutsem E. Geva R, et al. Among authors: prenen h. J Surg Oncol. 2010 Dec 15;102(8):937-45. doi: 10.1002/jso.21760. J Surg Oncol. 2010. PMID: 21165996 Review.

8

Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents.

Costa A, Tejpar S, Prenen H, Van Cutsem E. Costa A, et al. Among authors: prenen h. Target Oncol. 2011 Dec;6(4):227-33. doi: 10.1007/s11523-011-0200-y. Epub 2011 Nov 24. Target Oncol. 2011. PMID: 22113391 Review.

9

Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.

Siena S, Rivera F, Taieb J, Peeters M, Prenen H, Koukakis R, Demonty G, Köhne CH. Siena S, et al. Among authors: prenen h. Clin Colorectal Cancer. 2018 Mar;17(1):50-57.e8. doi: 10.1016/j.clcc.2017.09.006. Epub 2017 Sep 28. Clin Colorectal Cancer. 2018. PMID: 29096990 Free article.

10

Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review.

Schöffski P, Dumez H, Clement P, Hoeben A, Prenen H, Wolter P, Joniau S, Roskams T, Van Poppel H. Schöffski P, et al. Among authors: prenen h. Ann Oncol. 2006 Aug;17(8):1185-96. doi: 10.1093/annonc/mdj133. Epub 2006 Jan 17. Ann Oncol. 2006. PMID: 16418310 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

184 results

Search Page

Filters